Peter A LeWitt

Summary

Affiliation: SBM Consulting
Country: USA

Publications

  1. ncbi request reprint Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
    Peter A LeWitt
    Clinical Neuroscience Center, Southfield, MI 48034, USA
    Neurology 68:1262-7. 2007
  2. ncbi request reprint Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine, and Henry Ford Hospital Franklin Pointe Medical Center, 26400 West 12 Mile Road, Southfield, MI 48034, USA
    Clin Neuropharmacol 30:256-65. 2007
  3. doi request reprint Protection against Parkinson's disease progression: clinical experience
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Detroit, Michigan, USA
    Neurotherapeutics 5:210-25. 2008
  4. doi request reprint Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Southfield, MI 48034, USA
    Ann Neurol 63:295-302. 2008
  5. ncbi request reprint Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, Michigan, USA
    Mov Disord 24:1319-24. 2009
  6. doi request reprint Levodopa therapeutics for Parkinson's disease: new developments
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, and the Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48034, USA
    Parkinsonism Relat Disord 15:S31-4. 2009
  7. doi request reprint Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine and Henry Ford Hospital, Detroit, MI 48034, USA
    Clin Neuropharmacol 32:89-93. 2009
  8. ncbi request reprint Clinical trials of neuroprotection for Parkinson's disease
    Peter A LeWitt
    Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, The William Beaumont Hospital Research Institute, Royal Oak, Michigan, USA
    Neurology 63:S23-31. 2004
  9. pmc Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
    J Neural Transm 120:1069-81. 2013
  10. doi request reprint Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
    Peter A LeWitt
    Departments of Neurology, Henry Ford Hospital, Detroit, MI, USA
    Neurology 79:163-9. 2012

Detail Information

Publications27

  1. ncbi request reprint Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
    Peter A LeWitt
    Clinical Neuroscience Center, Southfield, MI 48034, USA
    Neurology 68:1262-7. 2007
    ..In patients experiencing motor fluctuations, a major treatment challenge is the reduction of "off" time, particularly upon awakening. Rotigotine (Neupro) is a novel dopaminergic agonist with 24-hour transdermal delivery...
  2. ncbi request reprint Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine, and Henry Ford Hospital Franklin Pointe Medical Center, 26400 West 12 Mile Road, Southfield, MI 48034, USA
    Clin Neuropharmacol 30:256-65. 2007
    ....
  3. doi request reprint Protection against Parkinson's disease progression: clinical experience
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Detroit, Michigan, USA
    Neurotherapeutics 5:210-25. 2008
    ..Beyond small-molecule pharmacology, gene therapy approaches, such as delivering neurotrophic substances (e.g., neurturin) by viral vector, are the next generation of treatment options...
  4. doi request reprint Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Southfield, MI 48034, USA
    Ann Neurol 63:295-302. 2008
    ..Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A(2A) receptor antagonist, istradefylline, shows promise for the treatment of PD...
  5. ncbi request reprint Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, Michigan, USA
    Mov Disord 24:1319-24. 2009
    ..803), and "on state with nontroublesome dyskinesia" was 18% for CLE and 7% for CL-CR (P = 0.03). Despite less "off" time with CLE, both formulations demonstrated similar mean PK values and marked intersubject PK variability...
  6. doi request reprint Levodopa therapeutics for Parkinson's disease: new developments
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, and the Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48034, USA
    Parkinsonism Relat Disord 15:S31-4. 2009
    ..This new research offers promise for improving outcomes with this highly effective therapy...
  7. doi request reprint Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine and Henry Ford Hospital, Detroit, MI 48034, USA
    Clin Neuropharmacol 32:89-93. 2009
    ..To assess the safety and adverse effect profile of continued use of intermittent subcutaneous apomorphine to treat "off" episodes in subjects with advanced Parkinson disease...
  8. ncbi request reprint Clinical trials of neuroprotection for Parkinson's disease
    Peter A LeWitt
    Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, The William Beaumont Hospital Research Institute, Royal Oak, Michigan, USA
    Neurology 63:S23-31. 2004
  9. pmc Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
    J Neural Transm 120:1069-81. 2013
    ..2 points below baseline, respectively, at end of treatment. In these open-label studies, adjunctive rotigotine was efficacious with an acceptable safety and tolerability profile in patients with advanced PD for up to 6 years...
  10. doi request reprint Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
    Peter A LeWitt
    Departments of Neurology, Henry Ford Hospital, Detroit, MI, USA
    Neurology 79:163-9. 2012
    ..The primary study objective was to assess suppression of LID by fipamezole at day 28, as measured by the levodopa-induced dyskinesia scale (LIDS), a modification of the abnormal involuntary movement scale...
  11. ncbi request reprint Subcutaneously administered apomorphine: pharmacokinetics and metabolism
    Peter A LeWitt
    Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA
    Neurology 62:S8-11. 2004
    ..The complexities of apomorphine uptake, distribution, and clearance probably contribute to its variability of clinical actions...
  12. doi request reprint Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, West Bloomfield, Michigan, USA Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA
    Mov Disord 29:75-82. 2014
    ..XP21279-carbidopa significantly reduced variability in levodopa concentrations compared with carbidopa-levodopa...
  13. pmc Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease
    Dianne M Camp
    Division of Neurology, William Beaumont Hospital Research Institute, Royal Oak, Michigan 48073, USA
    J Neuroinflammation 6:17. 2009
    ....
  14. ncbi request reprint New developments in levodopa therapy
    Peter A LeWitt
    Department of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, Michigan, USA
    Neurology 62:S9-16. 2004
    ..Evidence suggests that altering the delivery of levodopa to provide a more continuous supply of this drug to the brain may result in improved control of PD symptoms...
  15. ncbi request reprint Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?
    Peter A LeWitt
    From the Department of Neurology P A L, Henry Ford Hospital, Bloomfield the Department of Neurology P A L, Wayne State University School of Medicine, Detroit, MI and Center for Neurodegenerative and Neuroimmunologic Diseases M M M, Department of Neurology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ
    Neurology 82:1574-5. 2014
    ..However, fundamental questions about LID remain: by what mechanisms does it develop, and why don't all patients go on to experience LID after sustained levodopa exposure? ..
  16. ncbi request reprint 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, West Bloomfield, Michigan, USA School of Medicine, Wayne State University, Detroit, Michigan, USA
    Mov Disord 28:1653-60. 2013
    ..The findings support involvement of excitotoxicity and oxidative stress in the pathogenesis of PD...
  17. doi request reprint Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, West Bloomfield, MI 48322, USA
    Clin Neuropharmacol 35:103-10. 2012
    ....
  18. ncbi request reprint Lack of evidence for Nocardia asteroides in brain specimens from Lewy body-containing disorders
    Lin Lu
    Department of Neurology, William Beaumont Hospital Research Institute, 3601 West Thirteen Mile Road, Royal Oak, MI 48073, USA
    Microb Pathog 39:205-11. 2005
    ..4%; one case each of PD, DLB, and Alzheimer's disease), and none of the specimens was positive for Nocardia by PCR or Gram staining. These findings do not support an association of Nocardia with Lewy body-containing disorders...
  19. doi request reprint AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
    Peter A LeWitt
    Wayne State University School of Medicine, Parkinson s Disease and Movement Disorders Program, Henry Ford West Bloomfield Hospital, MI, USA
    Lancet Neurol 10:309-19. 2011
    ..We aimed to assess the effect of bilateral delivery of AAV2-GAD in the subthalamic nucleus compared with sham surgery in patients with advanced Parkinson's disease...
  20. ncbi request reprint Apomorphine therapy in Parkinson's disease: a review
    Ihtsham Ul Haq
    Movement Disorders Program, University of Florida, Department of Neurology McKnight Brain Institute, 100 S Newell Drive, PO Box 100236, Gainesville, Florida 32610 0236, USA
    Expert Opin Pharmacother 8:2799-809. 2007
    ..In this review, the authors discuss the history, pharmacology, efficacy, safety and proper administration of apomorphine for treating 'off' states in Parkinson's disease, with a focus on intermittent subcutaneous administration...
  21. ncbi request reprint Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
    Matthew B Stern
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 19:916-23. 2004
    ..05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline-treated and placebo-treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD...
  22. ncbi request reprint A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition
    Peter A LeWitt
    Clin Neuropharmacol 30:305-7. 2007
  23. ncbi request reprint TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 5:1013-20. 2006
    ..TCH346 is a potent anti-apoptotic drug that protects against loss of dopaminergic neurons in laboratory models. Our aim was to assess TCH346 as a neuroprotective drug in patients with Parkinson's disease...
  24. doi request reprint Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Clin Neuropharmacol 31:63-73. 2008
    ..This is a retrospective analysis of the long-term clinical experience with this agent...
  25. ncbi request reprint Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 22:41-7. 2007
    ....
  26. ncbi request reprint Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program
    Christopher G Goetz
    Department of Neurological Sciences, Rush University, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois, USA
    Mov Disord 18:1455-8. 2003
    ..The written materials and videotape belong to the Movement Disorder Society and are available by contacting the MDS central office...

Research Grants5

  1. Nocardia: A Novel Environmental Agent For Parkinsonism?
    Peter LeWitt; Fiscal Year: 2003
    ..These outcomes will be significant because they should add to our understanding of the neurodegenerative process in PD, and could lead to improved means of diagnosis and treatment for individuals with this disorder. ..
  2. Nocardia: A Novel Environmental Agent For Parkinsonism?
    Peter LeWitt; Fiscal Year: 2001
    ..These outcomes will be significant because they should add to our understanding of the neurodegenerative process in PD, and could lead to improved means of diagnosis and treatment for individuals with this disorder. ..
  3. Nocardia: A Novel Environmental Agent For Parkinsonism?
    Peter LeWitt; Fiscal Year: 2002
    ..These outcomes will be significant because they should add to our understanding of the neurodegenerative process in PD, and could lead to improved means of diagnosis and treatment for individuals with this disorder. ..
  4. Southeastern Michigan Parkinson's Disease Program
    Peter LeWitt; Fiscal Year: 2002
    ..This application also discusses concepts for three pharmacological agents that could be investigated in pilot studies and, if promising, in multicenter clinical trials for assessing neuroprotection. ..
  5. Southeastern Michigan Parkinson's Disease Program
    Peter LeWitt; Fiscal Year: 2006
    ..This application also discusses concepts for three pharmacological agents that could be investigated in pilot studies and, if promising, in multicenter clinical trials for assessing neuroprotection. ..